Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, Wegovy (semaglutide) can cause a faster-than-usual heart rate in some people. Clinical trials recorded an average increase of around one to four beats per minute at the 2.4mg maintenance dose, and a small proportion of participants noticed their pulse felt noticeably quicker — particularly in the weeks after a dose increase. It is a recognised, if less-discussed, side effect listed in the NHS patient information for semaglutide. That said, for most people it is mild and temporary. Wegovy is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is clinically appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people starting Wegovy notice their heart beating a little faster and immediately assume the medicine is harming them. That fear is understandable. But the modest pulse increase seen in trials is a pharmacological effect of GLP-1 receptor agonists on the autonomic nervous system, not a sign of cardiac damage. It is in the same category as nausea or a mild headache: your body responding to a new medicine, not signalling danger.
The STEP 1 trial, published in the New England Journal of Medicine, enrolled nearly 2,000 adults without diabetes and followed them for 68 weeks. Participants on the 2.4mg dose saw an average heart rate rise of roughly one to four beats per minute above baseline. That is the same order of magnitude as a brisk walk to the kettle. For the vast majority it caused no symptoms at all.
Where the picture changes is for a subset of people who experience palpitations (a fluttery or pounding awareness of the heartbeat) especially in the first few weeks at a new dose. This is listed as an uncommon side effect. It is worth noting, and worth mentioning to your prescriber, but it rarely requires stopping treatment.
GLP-1 receptors are found not just in the gut and brain but in cardiac tissue. When semaglutide activates those receptors, the result can include a modest increase in the rate at which the sinoatrial node fires, raising resting pulse slightly. It is a direct effect of the drug's mechanism, not a consequence of weight loss (which typically lowers heart rate over time) and not a sign of cardiovascular strain.
The net cardiovascular picture with semaglutide is actually positive for people at elevated risk. The SELECT trial demonstrated that semaglutide 2.4mg significantly reduced the risk of major cardiovascular events in adults with obesity and established cardiovascular disease. A small tick upward in resting heart rate sits alongside a meaningful reduction in heart attack and stroke risk. The two facts coexist without contradiction.
If you are curious about how Wegovy affects heart rate and where that fits into the broader conversation about the cardiovascular system, our overview of Wegovy and heart rate sets out the full picture.
There is a difference between a resting pulse that has nudged from 68 to 72 beats per minute and one that is sitting above 100 consistently, or that comes with chest tightness, breathlessness, or dizziness. The first is an expected pharmacological response. The second warrants clinical review.
Seek prompt medical advice if:
You can also report any suspected side effect directly through the MHRA Yellow Card scheme, which exists precisely so real-world data on medicines like Wegovy can be monitored. Our prescribers are available seven days a week if you have questions mid-treatment, the contact page has all the details.
For people who had a pre-existing elevated resting pulse before starting, or who are on other medicines that affect heart rhythm, the prescriber assessment at the outset is where these nuances are weighed up. Our FAQs cover a range of questions that come up at that stage.
A modest rise in resting heart rate should not, on its own, put you off a medicine that has strong trial evidence for sustained weight loss and (in the right population) meaningful cardiovascular protection. What it means practically is this: monitor how you feel, take your pulse if you have any awareness of your heartbeat, and tell your prescriber. That is straightforward clinical management, not cause for alarm.
If you are already taking Wegovy and noticing a faster pulse, our page on Wegovy and a fast heart rate explains what is typical and what is worth flagging to your prescriber. Our page on whether Wegovy can cause a rapid heart rate goes into more detail on what the dose-increase pattern looks like in practice.
For anyone weighing up semaglutide against other options, Wegovy's full profile, including licensed doses and how eligibility works, is covered on our Wegovy treatment page. And if you are thinking about the cost side of private treatment, the weight-loss treatments page sets out exactly what is included in one transparent price, consultation, prescription, and next-working-day delivery, with no hidden charges.
Speak to our prescribers if you have specific questions about heart rate and your own circumstances. If you want a straightforward answer to whether Wegovy can cause a high heart rate, that page covers what the clinical evidence says and when to seek further advice. Every consultation is reviewed by a GPhC-registered Independent Prescriber the same day (a real clinician reads your answers, not an automated system) and aftercare is available seven days a week once you are on treatment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.